DK2424505T3 - Multikomponent bioaktiv intravaginal ring - Google Patents
Multikomponent bioaktiv intravaginal ring Download PDFInfo
- Publication number
- DK2424505T3 DK2424505T3 DK08836926.9T DK08836926T DK2424505T3 DK 2424505 T3 DK2424505 T3 DK 2424505T3 DK 08836926 T DK08836926 T DK 08836926T DK 2424505 T3 DK2424505 T3 DK 2424505T3
- Authority
- DK
- Denmark
- Prior art keywords
- contraceptive
- multicomponent
- ring
- agents
- intravaginal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
Claims (11)
1. Indretning der omfatter en multikomponent, mikrobicid, kontraceptiv, intravagi-nal ringformet sigte, som omfatter en ringformet konstruktion der omfatter en ring-matrix, som omslutter en fibrøs sigte der er forbundet dertil og fastholdt i hulrummet af ringen, og en polymer belægning der dækker den ringformede konstruktion, hvor hver af ringmatrixen og den polymere belægning omfatter mindst et lægemiddelfrigivende polymersubstrat til uafhængigt at styre frigivelse af mindst et kontraceptivt middel og mindst et bioaktivt middel, og hvor det mindst ene bioaktive middel er valgt fra gruppen, der består af metronidazol, miconazol, keto-conazol, fluconazol, tobramycin, rapamycin, amphotericin, 5-flurocytosin, ciprofloxacin, tetracyclin, doxycyclin, zidovudin, acyclovir, penciclovir, ganciclovir, ci-dofovir, lamivudin, zalcitabin, valacyclovir, stavudin, ritonavir, indinavir, didano-sin, dideoxyadinosin, paclitaxel, mitomycin, 5- flurouracil, leflunomid, enfuvirtid, clotrimazol, terbinafin, chlorhexidin, mafenid, clindamycin, gemcitabin, erythromycin, ofloxacin, ceftriaxon og cefpodoxim, hvor ringmatrixen omfatter silicone, og hvor den fibrøse sigte omfatter polyester og hvor ringmatrixen indeholder mindst et kontraceptivt middel, og hvor den polymere belægning indeholder mindst et af de bioaktive midler.
2. Indretningen der omfatter en multikomponent, mikrobicid, kontraceptiv, intra-vaginal ringformet sigte ifølge krav 1, hvor den fibrøse sigte omfatter en absorberbar strikket sigte med en gennemsnitlig porediameter på mere end ca. 100 mikron, hvor ringen indeholder mindst et ikke-hormonalt spermiostatisk/spermi-cidt middel, og hvor den polymere belægning omfatter mindst et potent bioaktivt middel, som er valgt fra gruppen, der består af metronidazol, mikronazol, ketoco-nazol, fluconazol, tobramycin, rapamycin, amphotericin, 5-flurocytosin, penciclovir, acyclovir, en kombination af zidovudin og lamivudin, mitomycin, 5- flurouracil, leflunomid, enfuvirtid, gemcitabin og paclitaxel.
3. Indretningen omfattende en multikomponent, mikrobicid, kontraceptiv, intrava-ginal ringformet sigte ifølge krav 1, hvor ringmatrixen indeholder mikropartikler af ferrogluconat, ascorbinsyre, glycin og polyglycolsyre, og hvor den polymere belægning indeholder mindst et af de bioaktive midler der er udvalgt fra gruppen, som består af antibakterielle midler, antisvampemidler, antivirale midler, antire-trovirale midler, antineoplastiske midler, antiinflammatoriske midler.
4. Indretningen omfattende en multikomponent, mikrobicid, kontraceptiv, intrava-ginal ringformet sigte ifølge krav 3, hvor det mindst ene bioaktive middel er valgt fra gruppen, der består af metronidazol, miconazol, ketoconazol, fluconazol, tobramycin, rapamycin, amphotericin, 5-flurocytosin, ciprofloxacin, tetracyclin, doxycyclin , zidovudin, acyclovir, penciclovir, ganciclovir, cidofovir, lamivudin, za-Icitabin, valacyclovir, stavudin, ritonavir, indinavir, didanosin, dideoxyadinosin, clotrimazol, terbinafin, chlorhexidin, mafenid, clindamycin, paclitaxel, mitomycin, 5-fluorouracil, leflunomid, enfuvirtid, gemcitabin, erythromycin, ofloxacin, ceftria-xon og cefpodoxim.
5. Indretningen omfattende en multikomponent, mikrobicid, kontraceptiv, intrava-ginal ringformet sigte ifølge krav 1, hvor den polymere belægning omfatter en hydrofil polymer der omfatter en polyethylenglycol, og en hydrofob polymer der omfatter en absorberbar polyaxial copolyester.
6. Indretningen omfattende en multikomponent, mikrobicid, kontraceptiv, intrava-ginal ringformet sigte ifølge krav 1, hvor den fibrøse sigte af polyester er kemisk behandlet til at danne en polyanionisk overflade til at afstøde negativt ladede spermier og immobilisere kationiske bioaktive midler.
7. Indretningen omfattende en multikomponent, mikrobicid, kontraceptiv, intrava-ginal ringformet sigte ifølge krav 3, hvor den polymere belægning indeholder mindst et antiretroviralt middel og mindst et andet bioaktivt middel, hvilket antire-trovirale middel har forstærket eller støttet aktivitet der er induceret af det mindst ene af det andet bioaktive middel.
8. Indretningen omfattende en multikomponent, mikrobicid, kontraceptiv, intrava-ginal ringformet sigte ifølge krav 7, hvor det mindst ene af det andet bioaktive middel er valgt fra gruppen, der består af metronidazol, clindamycin, gentamicin, neomycin, tetracyclin, mitomycin, 5-fluoruracil, leflunomid, enfuvirtid, gemcitabin, paclitaxel, miconazol, ketoconazol, fluconazol, tobramycin, rapamycin, amphotericin, 5-flurocytosin, clotrimazol, et chlorhexinsalt og mafenid.
9. Indretningen omfattende en multikomponent, mikrobicid, kontraceptiv, intrava-ginal ringformet sigte ifølge krav 3, hvor den polymere belægning indeholder mindst et antiretroviralt middel som er valgt fra gruppen, der består af zidovudin, lamivudin, enfuvirtid og gemcitabin og mindst et andet bioaktivt middel, hvilket antiretrovirale middel har forøget eller støttet aktivitet der er induceret af det mindst ene af det andet bioaktive middel.
10. Indretningen omfattende en multikomponent, mikrobicid, kontraceptiv, intra-vaginal ringformet sigte ifølge krav 9, hvor det mindst ene af det andet bioaktive middel er valgt fra gruppen, der består af metronidazol, miconazol, ketoconazol, fluconazol, tobramycin, rapamycin, amphotericin, 5-flurocytosin, clotrimazol, mafenid, et chlorhexidinsalt, tetracyclin, neomycin, mitomycin, gemcitabin, gentamicin og clindamycin.
11. Indretningen omfattende en multikomponent, mikrobicid, kontraceptiv, intra-vaginal ringformet sigte ifølge krav 1 til supplerende anvendelse til forebyggelse og behandling af vævsinflammation, herpes, livmoderhalskræft, HIV og andre re-trovirale, virale og seksuelt overførte sygdomme.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/974,140 US8062658B2 (en) | 2004-12-14 | 2007-10-11 | Multicomponent bioactive intravaginal ring |
PCT/US2008/011617 WO2009048594A2 (en) | 2007-10-11 | 2008-10-09 | Multicomponent bioactive intravaginal ring |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2424505T3 true DK2424505T3 (da) | 2018-07-30 |
Family
ID=40550555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08836926.9T DK2424505T3 (da) | 2007-10-11 | 2008-10-09 | Multikomponent bioaktiv intravaginal ring |
Country Status (12)
Country | Link |
---|---|
US (2) | US8062658B2 (da) |
EP (1) | EP2424505B1 (da) |
CY (1) | CY1120879T1 (da) |
DK (1) | DK2424505T3 (da) |
ES (1) | ES2682111T3 (da) |
HR (1) | HRP20181108T1 (da) |
HU (1) | HUE038934T2 (da) |
LT (1) | LT2424505T (da) |
PL (1) | PL2424505T3 (da) |
PT (1) | PT2424505T (da) |
SI (1) | SI2424505T1 (da) |
WO (1) | WO2009048594A2 (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8399013B2 (en) * | 2003-06-26 | 2013-03-19 | Poly-Med, Inc. | Partially absorbable fiber-reinforced composites for controlled drug delivery |
US8404272B2 (en) | 2003-06-26 | 2013-03-26 | Poly-Med, Inc. | Fiber-reinforced composite rings for intravaginal controlled drug delivery |
US8062658B2 (en) | 2004-12-14 | 2011-11-22 | Poly-Med, Inc. | Multicomponent bioactive intravaginal ring |
US9034365B2 (en) * | 2008-05-20 | 2015-05-19 | Poly-Med, Inc. | Biostable, multipurpose, microbicidal intravaginal devices |
US20100120707A1 (en) * | 2008-09-16 | 2010-05-13 | Playtex Products, Llc | Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same |
PL2381932T3 (pl) * | 2009-01-29 | 2019-01-31 | Fondazione Irccs Istituto Nazionale Dei Tumori | Urządzenie wewnątrzszyjkowe do uwalniania leków w miejscowo- regionalnym leczeniu nowotworu szyjki macicy |
US9006278B2 (en) * | 2010-02-02 | 2015-04-14 | Poly-Med, Inc. | Controlled release systems of pluribioactive antifungal drugs and applications thereof |
EP2598114A1 (en) * | 2010-07-28 | 2013-06-05 | Fondazione Irccs "Istituto Nazionale del Tumori" | Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system. |
US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
AU2011325975B2 (en) | 2010-11-12 | 2015-11-26 | The University Of Utah Research Foundation | Intravaginal devices for controlled delivery of lubricants |
US9393216B2 (en) | 2012-11-06 | 2016-07-19 | University Of Washington Through Its Center For Commercialization | Vaginal matrices: nanofibers for contraception and prevention of HIV infection |
US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
CN103735547B (zh) * | 2013-12-31 | 2015-08-19 | 哈尔滨欧替药业有限公司 | 双唑泰阴道膨胀栓控释制剂及其制法 |
CN106456838B (zh) * | 2014-04-01 | 2020-12-29 | 保利医学公司 | 避孕装置及相关装置 |
BR112018005200A2 (pt) | 2015-09-16 | 2018-10-09 | Dfb Soria Llc | liberação de nanopartículas de fármaco e métodos de uso dos mesmos |
US20170087344A1 (en) * | 2015-09-25 | 2017-03-30 | Therapeutic Solutions International, Inc. | Devices and methods for reducing the risk of preterm labor and preterm birth |
ES2955884T3 (es) | 2017-03-15 | 2023-12-07 | Dfb Soria Llc | Terapia tópica para el tratamiento de malignidades de la piel con nanoparticulas de taxanos |
CA3067906A1 (en) * | 2017-06-28 | 2019-01-03 | Aicuris Anti-Infective Cures Gmbh | Intravaginally applicable devices comprising antiviral compounds |
JP7372252B2 (ja) | 2018-03-16 | 2023-10-31 | ディーエフビー ソリア リミテッド ライアビリティ カンパニー | タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍(cin)および子宮頸癌の処置のための局所療法 |
JP2023501570A (ja) * | 2019-11-12 | 2023-01-18 | ポリ-メッド インコーポレイテッド | 避妊用医療器具 |
BR112022009721A2 (pt) * | 2019-11-18 | 2022-08-09 | Dare Bioscience Inc | Dispositivos de anel intravaginal |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4629449A (en) | 1982-07-29 | 1986-12-16 | Alza Corporation | Vaginal dispenser for dispensing beneficial hormone |
US6416779B1 (en) | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
EP0891783B1 (en) | 1997-07-16 | 2002-06-12 | IsoTis N.V. | Device for tissue engineering bone comprising biodegradable thermoplastic copolyester and cultured cells |
US7416559B2 (en) | 2000-10-27 | 2008-08-26 | Poly-Med, Inc. | Micromantled drug-eluting stent |
WO2004004661A2 (en) | 2002-07-09 | 2004-01-15 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
US20040260386A1 (en) | 2003-01-31 | 2004-12-23 | Shalaby Shalaby W. | Absorbable / biodegradable tubular stent and methods of making the same |
US8404272B2 (en) | 2003-06-26 | 2013-03-26 | Poly-Med, Inc. | Fiber-reinforced composite rings for intravaginal controlled drug delivery |
US8399013B2 (en) | 2003-06-26 | 2013-03-19 | Poly-Med, Inc. | Partially absorbable fiber-reinforced composites for controlled drug delivery |
US20060240071A1 (en) * | 2003-07-31 | 2006-10-26 | Sidney Lerner | Non-hormonal vaginal contraceptive |
EP1687043A2 (en) | 2003-11-20 | 2006-08-09 | Angiotech International Ag | Electrical devices and anti-scarring agents |
US20050208095A1 (en) * | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
PT1768625E (pt) * | 2004-07-09 | 2011-04-18 | Hra Pharma Lab | Composições de libertação sustida contendo moduladores do receptor da progesterona |
US8062658B2 (en) | 2004-12-14 | 2011-11-22 | Poly-Med, Inc. | Multicomponent bioactive intravaginal ring |
EP1827328B1 (en) | 2004-12-14 | 2011-08-17 | Poly-Med, Inc. | Intravaginal ringed mesh device |
EP1829332A2 (en) | 2004-12-15 | 2007-09-05 | Exostar Corporation | Enabling trust in a federated collaboration of networks |
US8952075B2 (en) | 2008-05-22 | 2015-02-10 | Poly-Med, Inc. | Bioactive polymeric liquid formulations of absorbable, segmented aliphatic polyurethane compositions |
-
2007
- 2007-10-11 US US11/974,140 patent/US8062658B2/en active Active
-
2008
- 2008-10-09 HU HUE08836926A patent/HUE038934T2/hu unknown
- 2008-10-09 LT LTEP08836926.9T patent/LT2424505T/lt unknown
- 2008-10-09 EP EP08836926.9A patent/EP2424505B1/en active Active
- 2008-10-09 PT PT08836926T patent/PT2424505T/pt unknown
- 2008-10-09 DK DK08836926.9T patent/DK2424505T3/da active
- 2008-10-09 ES ES08836926.9T patent/ES2682111T3/es active Active
- 2008-10-09 SI SI200831983T patent/SI2424505T1/sl unknown
- 2008-10-09 WO PCT/US2008/011617 patent/WO2009048594A2/en active Application Filing
- 2008-10-09 PL PL08836926T patent/PL2424505T3/pl unknown
-
2011
- 2011-10-13 US US13/272,351 patent/US8506988B2/en active Active
-
2018
- 2018-07-13 HR HRP20181108TT patent/HRP20181108T1/hr unknown
- 2018-08-06 CY CY20181100808T patent/CY1120879T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
LT2424505T (lt) | 2018-09-10 |
US20120024472A1 (en) | 2012-02-02 |
ES2682111T3 (es) | 2018-09-18 |
CY1120879T1 (el) | 2020-05-29 |
SI2424505T1 (sl) | 2018-09-28 |
US8506988B2 (en) | 2013-08-13 |
WO2009048594A3 (en) | 2009-07-30 |
EP2424505B1 (en) | 2018-05-09 |
EP2424505A2 (en) | 2012-03-07 |
HRP20181108T1 (hr) | 2018-09-07 |
PT2424505T (pt) | 2018-10-03 |
PL2424505T3 (pl) | 2018-10-31 |
WO2009048594A2 (en) | 2009-04-16 |
EP2424505A4 (en) | 2013-10-23 |
HUE038934T2 (hu) | 2018-12-28 |
US8062658B2 (en) | 2011-11-22 |
US20080069850A1 (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2424505T3 (da) | Multikomponent bioaktiv intravaginal ring | |
US8404272B2 (en) | Fiber-reinforced composite rings for intravaginal controlled drug delivery | |
US9566267B2 (en) | Biostable, multipurpose, microbicidal intravaginal devices | |
CN1306919C (zh) | 阴道内或经阴道治疗真菌、细菌、病毒或寄生虫感染的装置和方法 | |
US5492692A (en) | Coated products with potent anti-HIV and antimicrobial properties | |
EP1827328B1 (en) | Intravaginal ringed mesh device | |
JP2004506482A (ja) | 非ホルモン性腟内避妊用具 | |
US20190101669A1 (en) | Novel anti-microbial bandage contact lens with ocular drug delivery | |
Blakney et al. | Application of electrospun fibers for female reproductive health | |
Zoccali et al. | Antibacterial hydrogel coating in joint mega-prosthesis: Results of a comparative series | |
Major et al. | Implantable drug delivery systems | |
US5380523A (en) | High energy coprecipitate of nonoxynol oligomer, PVP and iodine having contraceptive and potent anti-HIV properties | |
JP7248614B2 (ja) | 避妊具及び関連した器具 | |
Traore et al. | Segmented intravaginal ring for the combination delivery of hydroxychloroquine and anti-CCR5 siRNA nanoparticles as a potential strategy for preventing HIV infection | |
Sobel et al. | Comparative study of intravaginal metronidazole and triple-sulfa therapy for bacterial vaginosis | |
Creatsas et al. | Safety and tolerability of the new contraceptive sponge Protectaid® | |
Karuppannan et al. | Electrospun Nanofibers in Drug Delivery | |
RU2209068C1 (ru) | Гель "соби", обладающий противовирусной активностью и трансдермальными свойствами для лечения вич-инфицированных больных | |
Hernandez | Translational evaluation of electrospun drug delivery systems: fabrication, pharmacokinetics, and tissue-specific host responses | |
McConville | Ian Major1, Sarah Lastakchi2, Maurice Dalton1 and | |
AYu et al. | Experimental evaluation of the features in the course of the wound process using an original wound dressing | |
WO2024062020A1 (en) | Biocompatible structured material and uses thereof | |
Efimova et al. | Synthetic polymeric materials for ophthalmology | |
KAWAMURA et al. | Effect of ofloxacin in the treatment of genitourinary tract infection with Ureaplasma urealyticum | |
Digenis et al. | Coated-Products with Potent Anti-HIV and Antimicrobial Properties |